Respiratory syncytial virus (RSV) was first described 160 years ago but was not officially 
INTRODUCTION
Respiratory syncytial virus (RSV) is the leading cause of serious lower respiratory tract disease requiring hospitalization of infants and children in the United States [1] [2] [3] [4] [5] [6] where it accounts for up to 120,000 hospitalizations annually in infants <12 months of age. 4, 7, 8 On a broader scale, RSV is the most common cause of childhood acute lower respiratory tract infection. 9 Costs associated with RSV-related hospitalization and outpatient visits for bronchiolitis are on the rise. 10, 11 The unique ability of RSV to evade maternal antibodies and infect infants very early in life increases the clinical impact of disease, due in part to narrow airways in infants that are susceptible to obstruction and an immature immune system in these children. In some cases, the clinical consequences of RSV-related illness do not end in childhood. Long-term studies of children hospitalized with RSV-related lower respiratory tract illness before age 24 months who were prospectively followed up for periods ranging from 18 to 25 years indicate that severe illness in early life is an independent risk factor for wheezing throughout childhood.
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Despite the seriousness of RSV illness and its complications, there were few accounts of its existence as a major viral pathogen before the 1950s.
DISCOVERY OF RSV AS A RESPIRATORY PATHOGEN
The initial description of infants with cough, wheezing, and respiratory difficulty resembling asthma 160 years ago is believed to be the first report of disease resembling RSV in young children (Table 1) . Almost 100 years later, a series of winter epidemics was described in which a severe viral infection associated with cough, dyspnea, fever, bronchiolitis, and pneumonia occurred in newborn infants. 16, 17 In October 
HISTORY OF RSV VACCINE DEVELOPMENT
The history of the initial efforts to develop an RSV vaccine began shortly after RSV was first 
96-98
Infants aged 2-6 months had high F glycoprotein antibody titers but had low G glycoprotein antibody titers. 97 Children aged 7-40 months had F and G antibody titers comparable with those found in children who were infected with RSV. There are many challenges to overcome before a successful RSV vaccine can be licensed for administration in very young infants. 109, 111, 114 The most daunting hurdle is that to prevent clinically significant illness and reinfection, the 
Cotton Rat
In a study conducted in Russia, Dreizin et al. were the first to demonstrate that RSV replicated in high titers throughout the respiratory tract of the common cotton rat (Sigmodon hispidus). 
